Alpharetta, GA – According to filings with the U.S. Securities and Exchange Commission, Virios Therapeutics is raising $2,129,867.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Greg Duncan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Virios Therapeutics

Virios Therapeutics is a clinical-stage biopharmaceutical company developing and commercializing innovative antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Overactive immune response related to activation of tissue resident Herpes Simplex Virus-1 (HSV-1) has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome (CFS) and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease.

To learn more about Virios Therapeutics, visit http://www.innovativemedconcepts.com/

Contact:
Greg Duncan, Chief Executive Officer
866-620-8655
https://www.linkedin.com/in/greg-duncan-94893616/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved